Drug updated on 3/28/2024
Dosage Form | Tablet (oral; drospirenone/estetrol 3 mg/14.2 mg) |
Drug Class | Contraceptives |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for use by females of reproductive potential to prevent pregnancy.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Nextstellis (drospirenone and estetrol) Prescribing Information. | 2023 | Mayne Pharma, Greenville, NC |
Randomized Controlled Trials
Document Title | Sex Distribution | Year | Source |
---|---|---|---|
Estetrol-drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in europe and russia. | 1,553Subjects F: 100% M: 0% | 2022 | An International Journal of Obstetrics and Gynaecology |
Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials. | 3,417Subjects F: 100% M: 0% | 2022 | Contraception |
Sex Distribution:
F:100%
M:0%
1553Subjects
Year:
2022
Source:An International Journal of Obstetrics and Gynaecology
Sex Distribution:
F:100%
M:0%
3417Subjects
Year:
2022
Source:Contraception